logo
Plus   Neg
Share
Email

Ascentage, Merck To Evaluate APG-115 In Combination With KEYTRUDA In Advanced Solid Tumors

Ascentage Pharma said that it reached a clinical collaboration with Merck & Co (MRK) to evaluate the combination of APG-115, Ascentage's MDM2-p53 inhibitor, and KEYTRUDA or pembrolizumab, Merck's anti-PD-1 therapy, for the treatment of patients with advanced solid tumors.

As per the deal, Ascentage will sponsor an open-label, multicenter, phase Ib/II study (NCT03611868) is designed to evaluate the safety and efficacy of APG-115 with KEYTRUDA in multiple cohorts of solid tumors. i,e., NSCLC, melanoma, Urothelial cancer, Liposarcoma, MPNST and ATM mutated/p53 WT tumors resistant or relapsed to PD-1/PD-L1 treatment or without previous PD-1/PD-L1 treatment.

The Phase II portion of the study has initiated and is expected to enroll 80 patients at multiple sites in the US.

Merck and Ascentage will use a joint development committee to exchange information about the study.

Preclinical studies demonstrated that APG-115 promoted the production of proinflammatory cytokines in T cells, enhanced CD4+ T cell activation, and increased PD-L1 expression on various tumor cells. Enhanced antitumor activity was demonstrated in various tumor models after APG-115 was combined with PD-1 blockade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The media mogul and Billionaire Sumner Redstone passed away on Tuesday at the age of 97, his family's holding company National Amusements said in a statement on Wednesday. He was Chairman Emeritus of ViacomCBS and chief executive officer of National Amusements. Customers in the U.S. are preferring digital or touchless payment methods due to concerns arising from the COVID-19 pandemic, a survey said. According to the survey by Rapyd Financial Network, the coronavirus pandemic has raised health and safety concerns around using cash and coins, and is accelerating the pre-existing trend toward digital transactions. American Airlines has extended its offer to waive change fees for customers who purchase tickets for travel, until December 31, 2020 in response to lower travel demand due to the coronavirus pandemic. This means that the travelers need not pay penalties for changing the origin and destination cities.
Follow RTT